Sanyo launches stand-alone cell processing workstation
Includes cGMP compliant equipment for aseptic processing
The CPWS is an alternative to a traditional cleanroom, providing a grade A or Class 100 aseptic environment in a compact unit, and saving approximately 35% of the operating costs usually required for a conventional cleanroom, the company says.
The self-contained workstation has a small footprint and is quick and easy to install. It includes cGMP compliant equipment for aseptic processing and is user-friendly in operation.
Current and future applications of the CPWS include regenerative organ development, and tissue regeneration such as skin, cartilage, alveolar bone, cornea, cardiac muscle, nerve, liver and pancreas.
“The CPWS provides a practical solution for biotech and pharmaceutical customers to manufacture advanced cell therapies and hospitals to develop cell therapies for use in clinical trials,” said Ron Dudek, new business development manager at Sanyo.
Individual docking incubators reduce both product mix-up and cross-contamination, the company says. An optional built-in centrifuge and cell observation microscope/monitor further reduce laboratory space requirements as well as improving aseptic processing.
By using an H2O2 decontamination process, the CPWS can be completely sterilised without heat and prepared for the next protocol within two hours.
The four-port glove box delivers more than a conventional Class II, Type A2 biological safety cabinet typically installed within a cleanroom to achieve the same level of contamination or cross-contamination prevention, the company says.
Gowning is not required, improving user comfort and productivity upon entrance and exit from the aseptic environment.
You may also like
Trending Articles
Upcoming event
You may also like
Design & Build
Scitech-EKIUM wins Cleanroom Technology Best Cleanroom Design Award
While the project faced significant delivery challenges, most notably construction on the 15th floor of a live hospital, the strength of the design itself lay in its adaptability, technical coordination, and strong alignment with user needs
Containment
FDA warning letter flags serious violations at New Jersey manufacturing facility for GLP-1 weight loss jabs
The US Food and Drug Administration has issued a warning letter of deficient cleanroom design, contamination controls and quality oversight in sterile GLP-1 drug production at a New Life Pharma facility
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.